Alan Meds vs Strut Health
A flat rate stated outright against a rate conditional on a standing order.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Alan Meds
Editorial
$99/mo
Alan Meds advertises compounded semaglutide at $99 a month by injection and $135 as an oral, with compounded tirzepatide at $145 by injection. The rates are stated as flat across doses. Forty-six states are served, and no oral tirzepatide is listed.
Pick it for: Readers who want no standing order and a stated flat rate
Strut Health
Partner
$99/mo
Strut Health advertises compounded semaglutide at $149 a month by injection and $99 as an oral, with compounded tirzepatide at $199 in either form. Each of those is the auto-refill rate; the page shows a higher one-off price beside the oral tirzepatide at $239, and a $325 compare-at figure beside the injection. Coverage runs to 49 states, with Alaska excluded.
Pick it for: Readers who want a tablet and will hold the refill to get it
Our verdict
Alan Meds states its figures hold at every dose. Strut Health's headline requires a refill commitment and it publishes the one-off price beside it. Both are $99 and neither means the same thing. The formats differ too: Alan Meds quotes $99 for an injection, while Strut Health's $99 is the oral and its injection is $149. Strut also states the discount behind each line, so a reader can see what stepping outside the standing order costs. Alan Meds has no standing order to step outside of, which is why it publishes one figure per line and no alternative.
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.